Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic.

Bookmark(0)

Cancer diagnostics and surgery have been disrupted by the response of healthcare services to the COVID-19 pandemic. Progression of cancers during delay will impact on patient long-term survival.We generated per-day […]

» Read more

Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic.

Bookmark(0)

Cancer diagnostics and surgery have been disrupted by the response of healthcare services to the COVID-19 pandemic. Progression of cancers during delay will impact on patient long-term survival.We generated per-day […]

» Read more

Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer.

Bookmark(0)

Alpelisib (α-selective PI3K inhibitor) plus fulvestrant is approved in multiple countries for men and post-menopausal women with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast […]

» Read more

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy.

Bookmark(1)

Anti-PD-1 antibodies (PD1) prolong recurrence-free survival in high-risk resected melanoma; however, approximately 25-30% of patients recur within one year. This study describes the pattern of recurrence, management and outcomes of […]

» Read more

Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas.

Bookmark(0)

Gastroesophageal adenocarcinomas (GEA) are heterogeneous cancers where immune checkpoint inhibitors (ICI) have robust efficacy in heavily inflamed microsatellite instability (MSI) or Epstein-Barr Virus (EBV) positive subtypes. ICI responses are markedly […]

» Read more

Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.

Bookmark(0)

In men with castration-sensitive prostate cancer (CSPC), the HSD3B1 c.1245A>C variant has been reported to associate with shorter responses to first-line androgen deprivation therapy (ADT). Here, we evaluated the association […]

» Read more

Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel.

Bookmark(0)

Primary tumor location (PTL) is being adopted by clinicians to guide treatment decisions in advanced colorectal cancer (aCRC). Here we test PTL as a predictive marker for panitumumab efficacy, and […]

» Read more

Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study.

Bookmark(0)

The impact of rituximab on health-related quality of life (HRQoL) in primary central nervous system lymphoma patients is not well-known. We determined the impact of rituximab added to standard high-dose […]

» Read more

Enrichment of Kinase Fusions in ESR1 Wild Type, Metastatic Breast Cancer Revealed by a Systematic Analysis of 4,854 Patients.

Bookmark(0)

Kinase fusions are rare and poorly characterized in breast cancer. We aimed to characterize kinase fusions within a large cohort of advanced breast cancer.4854 patients with breast cancer were analyzed […]

» Read more

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.

Bookmark(0)

The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) with first-line avelumab plus axitinib vs sunitinib in advanced renal cell carcinoma (aRCC). We report updated […]

» Read more

A multi-centre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer.

Bookmark(0)

The optimal duration of filgrastim as primary febrile neutropenia (FN) prophylaxis in early breast cancer (EBC) patients is unknown, with 5, 7 or 10 days being commonly prescribed. This trial […]

» Read more

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.

Bookmark(0)

Immune checkpoint inhibitors (ICIs) have been shown to be beneficial for some patients with advanced non-small cell lung cancer (NSCLC). However, the underlying mechanisms mediating the limited response to ICIs […]

» Read more

Deep learning radiomic nomogram can predict the number of lymph node metastasis in locally advanced gastric cancer: an international multi-center study.

Bookmark(0)

Preoperative evaluation of the number of lymph node metastasis (LNM) is the basis of individual treatment of locally advanced gastric cancer (LAGC). However, the routinely used preoperative determination method is […]

» Read more

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.

Bookmark(0)

Targeting the programmed cell death protein 1 (PD-1)/ligand (PD-L1) axis has demonstrated clinical benefit in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Combining immunotherapies targeting PD-L1 and cytotoxic […]

» Read more

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.

Bookmark(0)

The Immunoscore (IS), which prognostically classifies stage I-III colon cancer (CC) patients, was evaluated in the IDEA France cohort study investigating 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy in […]

» Read more

Clinical Outcomes in Men of Diverse Ethnic Backgrounds with Metastatic Castration Resistant Prostate Cancer.

Bookmark(0)

We have shown previously in multivariable analysis that black men had 19% lower risk of death than white men with metastatic castration resistant prostate cancer (mCRPC) treated with a docetaxel […]

» Read more

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.

Bookmark(0)

The phase Ib KEYNOTE-173 study was conducted to assess the safety and preliminary antitumor activity of neoadjuvant chemotherapy plus pembrolizumab in high-risk, early-stage, non-metastatic triple-negative breast cancer (TNBC).Six pembrolizumab plus […]

» Read more

Extrachromosomal DNA – relieving heredity constraints, accelerating tumour evolution.

Bookmark(0)

Oncogene amplification on extrachromosomal DNA (ecDNA) provides a mechanism by which cancer cells can rapidly adapt to changes in the tumour microenvironment. These circular structures contain oncogenes and their regulatory […]

» Read more

JSCO/ESMO/ASCO/JSMO/TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.

Bookmark(0)

A Japan Society of Clinical Oncology (JSCO)-hosted expert meeting was held in Japan on 27 October 2019 which comprised experts from the JSCO, the Japanese Society of Medical Oncology (JSMO), […]

» Read more

Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019.

Bookmark(0)

Aspirin has been associated with a reduced risk of colorectal cancer, and possibly of a few other digestive tract cancers. The quantification of risk reduction and the optimal dose and […]

» Read more

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.

Bookmark(0)

Little is known about mechanisms of resistance to poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) and platinum chemotherapy in patients with metastatic breast cancer and BRCA1/2 mutations. Further investigation of resistance in […]

» Read more
1 2 3 38